CSCO肺癌指南驱动基因阴性治疗策略V讲义.pptVIP

  • 8
  • 0
  • 约1.07万字
  • 约 35页
  • 2019-09-29 发布于江苏
  • 举报

CSCO肺癌指南驱动基因阴性治疗策略V讲义.ppt

17.Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabline induction chemotherapy in advanced NSCLC:IFCT-GFPC 0502 phase III study [abstract]. J Clin Oncol 2010;28 (Suppl 15): Abstract 7507. IFCT-GFPC 0502: 一线吉西他滨+顺铂,吉西他滨维持治疗 17.Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabline induction chemotherapy in advanced NSCLC:IFCT-GFPC 0502 phase II

文档评论(0)

1亿VIP精品文档

相关文档